2010 Scrip 100 - Pharma muscles into emerging markets with M&A
This article was originally published in Scrip
Executive Summary
This year has seen many firms facing patent expiries on core revenue generators. The current climate is driving M&A strategies, particularly in emerging markets and often with a focus on branded generics. Abbott has used M&A to propel itself to the top of the Indian market, writes Karen Beynon.